Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO-EURACAN Clinical Practice Guidelines for Uveal Melanoma

Stock Information for Delcath Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Delcath Systems Inc.

Delcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.